Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study

  1. Troya, J.
  2. Ryan, P.
  3. Ribera, E.
  4. Podzamczer, D.
  5. Hontañón, V.
  6. Terrón, J.A.
  7. Boix, V.
  8. Moreno, S.
  9. Barrufet, P.
  10. Castaño, M.
  11. Carrero, A.
  12. Galindo, M.J.
  13. Suárez-Lozano, I.
  14. Knobel, H.
  15. Raffo, M.
  16. Solõs, J.
  17. Yllescas, M.
  18. Esteban, H.
  19. González-Garcõa, J.
  20. Berenguer, J.
  21. Imaz, A.
Journal:
PLoS ONE

ISSN: 1932-6203

Year of publication: 2016

Volume: 11

Issue: 10

Type: Article

DOI: 10.1371/JOURNAL.PONE.0164455 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus